Hepatic Encephalopathy Management

Introduction to Treatment

• The American Association for the Study of Liver Diseases recommends lactulose as the first-line treatment for hepatic encephalopathy, with rifaximin as an effective add-on therapy for prevention of recurrence 1, 2, 3

Four-Pronged Approach to Management

• Initiate appropriate care for patients with altered consciousness, with intensive care monitoring for those with higher grades of HE who cannot protect their airway, as recommended by the European Association for the Study of the Liver 1, 4
• Identify and treat alternative causes of altered mental status that may coexist with HE, as suggested by the American Association for the Study of Liver Diseases 1, 4
• Identify and correct precipitating factors, which can resolve HE in nearly 90% of patients, according to the European Association for the Study of the Liver 1, 2, 5
• Commence empirical HE treatment without delay, as recommended by the American Association for the Study of Liver Diseases 1, 5

First-Line Treatment

• The American Association for the Study of Liver Diseases recommends starting lactulose at 25 mL orally every 12 hours, titrated to achieve 2-3 soft bowel movements daily 5, 4
• In patients unable to take oral medications, the European Association for the Study of the Liver suggests administering lactulose via nasogastric tube 1

Second-Line and Add-On Treatments

• Add rifaximin 550 mg twice daily when lactulose alone fails to prevent recurrence of HE, as recommended by the American Association for the Study of Liver Diseases 2, 3, 5
• Rifaximin reduces the risk of HE recurrence by 58% when added to lactulose, according to the European Association for the Study of the Liver 5, 4

Prevention of Recurrence

• The American Association for the Study of Liver Diseases strongly recommends secondary prophylaxis after an episode of overt HE 1, 3
• The European Association for the Study of the Liver recommends lactulose for prevention of recurrent episodes 3
• For patients with recurrent HE despite lactulose therapy, the American Association for the Study of Liver Diseases suggests adding rifaximin 550 mg twice daily 3

Special Considerations

• The American Association for the Study of Liver Diseases recommends considering liver transplantation in patients with recurrent intractable HE and liver failure 1, 5
• The European Association for the Study of the Liver suggests evaluating for large spontaneous portosystemic shunts that may be amenable to embolization in patients with preserved liver function and recurrent HE 3

Nutritional Considerations

• The European Association for the Study of the Liver recommends avoiding protein restriction as it can worsen malnutrition and sarcopenia, which are risk factors for HE 6
• The American Association for the Study of Liver Diseases suggests encouraging small meals distributed throughout the day and a late-night snack 6
• The European Association for the Study of the Liver recommends avoiding fasting periods which can worsen HE 6

Common Pitfalls to Avoid

• The American Association for the Study of Liver Diseases warns that overuse of lactulose can lead to complications such as aspiration, dehydration, hypernatremia, and perianal skin irritation 5
• The European Association for the Study of the Liver emphasizes the importance of identifying and treating precipitating factors to avoid poor treatment response 1, 5, 4

Hepatic Encephalopathy Management

Core Treatment Algorithm

• The American Association for the Study of Liver Diseases recommends lactulose as the first-choice treatment for episodic overt hepatic encephalopathy, achieving clinical response in approximately 75% of patients and reducing blood ammonia levels by 25-50% 7, 8
• Rifaximin should be added to lactulose after the second episode of hepatic encephalopathy or when lactulose alone fails to prevent recurrence, with standard dosing of 550 mg twice daily 7, 8
• The combination of rifaximin plus lactulose improves recovery from hepatic encephalopathy within 10 days and shortens hospital stays 7, 9

Alternative and Emerging Therapies

• IV L-ornithine L-aspartate can be used as an alternative or additional agent for patients nonresponsive to conventional therapy, with oral L-ornithine L-aspartate being ineffective 7, 8, 10, 11
• Oral branched-chain amino acids improve manifestations of episodic hepatic encephalopathy and can be used as alternative or additional therapy, with IV branched-chain amino acids being ineffective for acute episodes 7, 8, 10, 11, 9

Special Clinical Scenarios

• Neither rifaximin nor lactulose prevents post-TIPS hepatic encephalopathy better than placebo, and routine prophylactic therapy is not recommended 7
• Identifying and correcting precipitating factors, such as infection, GI bleeding, medications, and electrolyte disturbances, resolves hepatic encephalopathy in nearly 90% of patients 7, 8

Essential Management Principles

• Identifying and treating alternative causes of altered mental status that may coexist with hepatic encephalopathy is crucial 7, 8

Management of Overt Hepatic Encephalopathy

First‑Line Pharmacologic Therapy

• Lactulose is the recommended first‑choice agent for episodic overt hepatic encephalopathy and should be initiated without delay. The recommendation applies to adult patients with a new overt episode. 12
• Approximately three‑quarters of patients achieve clinical response to lactulose, with a concomitant 25‑50 % reduction in blood ammonia levels. Response is observed in adults treated for overt episodes. 12

Second‑Line/Adjunctive Pharmacologic Therapy

• Rifaximin 550 mg twice daily should be added when lactulose alone fails to prevent recurrence of hepatic encephalopathy. This applies to patients who have experienced at least one recurrence despite optimal lactulose dosing. 12
• In patients with recurrent overt episodes despite lactulose, adding rifaximin 550 mg twice daily is advised for secondary prevention. The addition targets adults with documented recurrence. 12

Alternative and Additional Therapies for Refractory Cases

• Intravenous L‑ornithine L‑aspartate can be employed as an alternative or adjunctive agent when lactulose and rifaximin are ineffective. Use is limited to acute refractory overt episodes. 12
• Oral branched‑chain amino acids may be used as an alternative or adjunctive therapy in refractory overt hepatic encephalopathy. Intended for adult patients with ongoing symptoms despite standard therapy. 12
• Neomycin is an alternative antimicrobial option, though long‑term use carries risks of ototoxicity and nephrotoxicity. Considered for patients unable to tolerate rifaximin or lactulose. 12
• Metronidazole can be used for short‑term therapy, but prolonged use is limited by risks of ototoxicity, nephrotoxicity, and neurotoxicity. Suitable for brief courses in acute settings. 12

Special Clinical Scenarios

Post‑TIPS Hepatic Encephalopathy

• Neither rifaximin nor lactulose demonstrates superiority over placebo in preventing hepatic encephalopathy after transjugular intra‑hepatic portosystemic shunt (TIPS) placement. Applies to adults undergoing TIPS. 12
• If severe hepatic encephalopathy develops after TIPS, reduction of the shunt diameter may reverse the encephalopathy. Intervention is considered for post‑TIPS patients with refractory symptoms. 12

Spontaneous Portosystemic Shunts

• In patients with preserved liver function who experience recurrent overt hepatic encephalopathy, large spontaneous portosystemic shunts should be sought and may be amenable to embolization. Target population: adults with recurrent overt episodes and adequate hepatic reserve. 12

Upper Gastrointestinal Bleeding

• Lactulose is supported for the prevention of hepatic encephalopathy following an episode of upper gastrointestinal bleeding. Recommendation applies to cirrhotic adults presenting with acute GI hemorrhage. 12